Differential diagnosis: Nociceptive and neuropathic pain

American Journal of Managed Care

Volumn 12, Issue SUPPL. 9, 2006, Pages

  Nicholson, Bruce ^a  

^a LEHIGH VALLEY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PAIN; CHRONIC PAIN; DIABETIC NEUROPATHY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; HERPES ZOSTER; HUMAN; NERVE TRACT; NEUROPATHIC PAIN; NOCICEPTION; PAIN; POSTHERPETIC NEURALGIA; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; TISSUE INJURY; UNITED STATES;

DIABETIC NEUROPATHIES; DIAGNOSIS, DIFFERENTIAL; HUMANS; NOCICEPTORS; PAIN; UNITED STATES;

EID: 33745615880     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. International Association for the Study of Pain. IASP Pain Terminology. 1994. Available at http://www.iasp-pain. org/terms-p.html. Accessed May 3, 2006.
2. Goucke CR. The management of persistent pain. Med J Aust. 2003;178:444-447.
3. American Academy of Pain Medicine. Management of chronic pain syndromes: issues and interventions. Pain Med. 2005;6(suppl 1):S1-S20.
4. Chen H, Lamer TJ, Rho RH, et al. Contemporary management of neuropathic pain for the primary care physician. Mayo Clin Proc. 2004;79:1533-1545.
5. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60: 1524-1534.
6. Martin LA, Hagen NA. Neuropathic pain in cancer patients: mechanisms, syndromes, and clinical controversies. J Pain Symptom Manage. 1997;14:99-117.
7. Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett. 2004;361:184-187.
8. Fukuoka T, Tokunaga A, Kondo E, Miki K, Tachibana T, Noguchi K. Change in mRNAs for neuropeptides and the GABA(A) receptor in dorsal root ganglion neurons in a rat experimental neuropathic pain model. Pain. 1998; 78:13-26.
9. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic nephropathy in the US. Diabetes Care. 2003;26:1790-1795.
10. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817-824.
11. National Diabetes Information Clearinghouse. National Diabetes Statistics. NIH Publication No. 06-3892. 2005. Available at: http://diabetes.niddk.nih. gov/dm/pubs/statistics/index.htm#7. Accessed May 3, 2006.
12. Boulton AJ. Treatment of symptomatic diabetic neuropathy. Diabetes Metab Res Rev. 2003;19(suppl 1): S16-S21.
13. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-986.
14. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18:350-354.
15. Quattrini C, Tesfaye S. Understanding the impact of painful diabetic neuropathy. Diabetes Metab Res Rev. 2003;19(suppl 1):S2-S8.
16. Greene DA, Stevens MJ, Feldman EL. Diabetic neuropathy: scope of the syndrome. Am J Med. 1999; 107(suppl 2B):2S-8S.
17. Herman WH, Kennedy L. Underdiagnosis of peripheral neuropathy in type 2 diabetes. Diabetes Care. 2005;28:1480-1481.
18. Bhadada SK, Sahay RK, Jyotsna VP, Agrawal JK. Diabetic neuropathy: current concepts. J Indian Acad Clin Med. 2001;2:305-318.
19. McElveen WA, Gonzalez RF. Postherpetic neuralgia. eMedicine. 2005. Available at: http://www.emedicine. com/neuro/topic317.htm. Accessed May 3, 2006.
20. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;63:959-965.
21. Stankus SJ, Dlugopolski M, Packer D. Management of herpes zoster (shingles) and postherpetic neuralgia. Am Fam Physician. 2000;61:2437-2444, 2447-2448.
22. Argoff CE, Katz N, Backonja M. Treatment of post-herpetic neuralgia: a review of therapeutic options. J Pain Symptom Manage. 2004;28:396-411.
23. Gilden D. Varicella zoster virus and central nervous system syndromes. Herpes. 2004;11(suppl 2):89A-94A.
24. Gazewood JD, Meadows S, Halverson L. Clinical inquiries. What is the prognosis of postherpetic neuralgia? J Fam Pract. 2003;52:496-497.
25. Schmader K, George LK, Burchett BM, Pieper CF, Hamilton JD. Racial differences in the occurrence of herpes zoster. J Infect Dis. 1995;171:701-704.
26. Oaklander AL. Evidence-based treatment of herpes zoster and postherpetic neuralgia. Pain Management Rounds. 2004;1:1-6.
27. Rowbotham MC, Petersen KL, Fields HL. Is post-herpetic neuralgia more than one disorder? IASP Newsletter. 1999. Available at: http://www.iasp-pain. org/TC99Fall.html. Accessed May 3, 2006.
28. Grond S, Radbruch L, Meuser T, Loick G, Sabatowski R, Lehmann KA. High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage. 1999;18:174-179.
29. Manfredi PL, Gonzales GR, Sady R, Chandler S, Payne R. Neuropathic pain in patients with cancer. J Palliat Care. 2003;19:115-118.
30. Mantyh PW. A mechanism based understanding of cancer pain. Pain. 2002;96:1-2.
31. Mantyh PW. A mechanism-based understanding of bone cancer pain. Novartis Found Symp. 2004;261:194-214.
32. Sevcik MA, Ghilardi JR, Peters CM, et al. Anti-NCF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain. 2005;115: 128-141.
33. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain. 1999;82:263-274.